Vivlion licenses CRISPR tech from ERS Genomics

By The Science Advisory Board staff writers

Vivlion has signed a nonexclusive license agreement to access ERS Genomics' CRISPR/Cas9 patent portfolio to enhance Vivlion's gene editing reagents and screening services.

Vivlioin, a German startup focused on next-generation CRISPR/Cas guide RNA (gRNA) libraries and screening services, holds an exclusive license to Goethe University of Frankfurt's proprietary 3Cs technology for the production of next-generation 3Cs CRISPR/Cas gRNA libraries.

The technology enables single and dual-combinatorial CRISPR/Cas libraries to be produced without compromising quality. This new license will enable Vivlion to offer both research and development reagents and screening services to its customers worldwide.

Financial details of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?